VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ONCY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ONCYOncolytics Biotech Inc.
$0.44$56M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ONCY logo

Oncolytics Biotech Inc.

ONCY
NASDAQ · Oncology Biotech
$0.44
At close - Nov 18, 4:00 PM EST - USD
Market Cap$56M
P/E-2.1x
52W High$1.30
Volume2.18M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Clinical Burn Threatens Future Capital Solvency

Oncolytics Biotech remains in a high-risk, pre-revenue development phase characterized by significant R&D expenditures and a rapidly deteriorating balance sheet.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

ONCY price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-107% Peers

P/E is 107% below peer median

03

Market leadership

RS 15 · Lag

Laggard (Underperforming 85% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 13

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ONCY-55.24%
S&P 500 (^GSPC)+6.88%
1-Year Return
ONCY-57.25%
S&P 500 (^GSPC)+10.62%
3-Year Return
ONCY-72.31%
S&P 500 (^GSPC)+68.13%
5-Year Return
ONCY-74.84%
S&P 500 (^GSPC)+76.76%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$29M-26.2% YoY
Free cash flow FY25
-$20M-0.3% YoY
Operating margin FY25
-
ROIC (FY25)-
Avg ROIC 5Y-369.7%
ROE (FY25)-7467.2%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 13, 2026
-$0.08-46.8%
vs -$0.05
—
vs —
Q3 2026
Aug 12, 2026
-$0.08-48.7%
vs -$0.05
—
vs —
Q2 2026
May 14, 2026
-$0.08-60.0%
vs -$0.05
—
vs —
Q2 2026
Mar 30, 2026
-$0.01+83.1%
vs -$0.06
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·5d ago
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC

Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carci

GlobeNewsWire·Nov 11, 2026
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma

Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carci

GlobeNewsWire·Nov 9, 2026
Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients

SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced translational data in heavily pretreated relapsed/refractory multiple myeloma patients, which will be presented at the 68th American Society of Hematology (“ASH”) Annual Meeting and Exposition. Title: Pelareorep induces innate and adaptive antiviral immune activation in relapsed/refractory multiple myeloma: Single-cell analysis from a Phase 1b/2 trial Abstract Number: 2183 Presentation Type: Poster Presentation Date: Saturday, December 12, 2026 Highlights from the abstract include: The Phase 1b/2 trial evaluated bortezomib (“BOR”), dexamethasone (“DEX”), and pembrolizumab (“Pemb”) in Cohort 1 and pelareorep plus BOR, DEX, and Pemb in Cohort 2 in patients with relapsed/refractory multiple myeloma.

GlobeNewsWire·Nov 4, 2026
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers

Pelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels more than doubled in nearly all patients after one cycle of treatment Substantial increases in HPV-16-specific T cells and tumor-infiltrating lymphocytes observed when pelareorep is combined with a checkpoint inhibitor SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced new translational data from an ongoing study showing pelareorep's ability to increase human papillomavirus (“HPV”)-16-specific T cell clones and tumor-infiltrating lymphocyte (“TIL”) clones in second-line or later squamous cell anal cancer (“SCAC”) patients at the Society for Immunotherapy of Cancer (“SITC”) 2026 Annual Meeting. Pelareorep combined with a checkpoint inhibitor generated promising efficacy signals in second-line or later SCAC, including more than doubling the objective response rate and increasing median duration of response by 50% compared to the current approved therapy in that patient population.

Filtered for Oncolytics Biotech Inc.More Headlines
04

Compare before deciding

Benchmark ONCY against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Oncolytics Biotech Inc. (ONCY)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ONCY logoONCYOncolytics Biotech Inc.Current
$0.44$56.31M-2.15——-7467.16%—
IMVT logoIMVTImmunovant, Inc.
$33.17$6.85B-13.47—-7173.52%-63.01%—
CLDX logoCLDXCelldex Therapeutics, Inc.
$27.55$1.83B-7.00-78.63%-275986.61%-52.67%—
NKTR logoNKTRNektar Therapeutics
$34.42$1.18B-6.64-43.89%-339.67%-29.31%—
VVOS logoVVOSVivos Therapeutics, Inc.
$0.08$1.06M-0.0516.05%-122.42%——
AMGN logoAMGNAmgen Inc.
$443.89$239.57B25.819.92%24.12%85.59%2.13%

Compare ONCY vs Peers

Oncolytics Biotech Inc. (ONCY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for ONCY.

Scale Benchmark

vs MRK

Larger-name benchmark to compare ONCY against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, CLDX, NKTR, VVOS

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ONCY SEC Filings & Documents

Oncolytics Biotech Inc. (ONCY) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 12, 2026·SEC

Material company update

Nov 9, 2026·SEC

Material company update

Nov 4, 2026·SEC

10-K Annual Reports

1
FY 2026

Mar 30, 2026·SEC

10-Q Quarterly Reports

3
FY 2026

Nov 13, 2026·SEC

FY 2026

Aug 12, 2026·SEC

FY 2026

May 14, 2026·SEC

Get notified when ONCY posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ONCY Frequently Asked Questions

Oncolytics Biotech Inc. (ONCY) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is ONCY profitable?

No. Oncolytics Biotech Inc. (ONCY) reported a net loss of $37.6M over the trailing twelve months.

Dividend & Returns
What is ONCY's return on equity?

Oncolytics Biotech Inc. (ONCY) had a return on equity (ROE) of -7467.2% in fiscal year 2025. A negative ROE means the company lost money over the period.

What is Oncolytics Biotech Inc.'s free cash flow?

Oncolytics Biotech Inc. (ONCY) had negative free cash flow of $29.1M over the trailing twelve months.

What if you invested $1,000 in ONCY back in 1999?

Total return calculator · dividends reinvested · 27+ years of data

See returns →